New heart plug aims to cut stroke risk without blood thinners
NCT ID NCT07385599
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new device called the LAmbre™ II, designed to close off a small pouch in the heart (the left atrial appendage) in people with atrial fibrillation who are at high risk for stroke. The goal is to prevent blood clots from forming there, potentially reducing stroke risk without needing lifelong blood thinners. Only 10 participants will be enrolled to check if the device is safe and works as intended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LAmbre™ II left atrial appendage occluder device
What this could lead to
If successful, this device could offer a way to lower stroke risk in atrial fibrillation patients without needing lifelong blood-thinning medication.
What could go wrong
This is a very early, small study with only 10 participants, so results may not apply broadly. There are risks like heart injury, device movement, or stroke during or shortly after the procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-VALVULAR ATRIAL FIBRILLATION (NVAF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prince of Wales Hospital, Chinese University of Hong Kong, HKSAR
RECRUITINGShatin, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••